do i read that correctly? $11mil is not bad amount after all.
Only for one indication, retinopathy of prematurity. Insmed retains the rights to IPLEX for other indications, some of which are blocked by a patent infringement judgement until 2018.
Was it just ROP, or "conditions of prematurity"? I haven't had time to look for this information. It has been a busy week. Thanks!